BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8323093)

  • 1. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
    Chanson P; Weintraub BD; Harris AG
    Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide.
    Chanson P; Warnet A
    Metabolism; 1992 Sep; 41(9 Suppl 2):62-5. PubMed ID: 1518435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
    Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
    Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
    Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
    Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Lee EJ; Kim KR; Lim SK; Lee HC; Kim DI; Kim SH; Huh KB
    Eur J Endocrinol; 1994 Jul; 131(1):109-12. PubMed ID: 8038902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
    Colao A; Merola B; Ferone D; Marzullo P; Cerbone G; Longobardi S; Di Somma C; Lombardi G
    Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
    Chayen SD; Gross D; Makhoul O; Glaser B
    Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P; Díez JJ
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
    Orme SM; Lamb JT; Nelson M; Belchetz PE
    Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
    Warnet A
    Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
    Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF; Liang D; Zhong LY
    Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
    Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
    Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA; Bernstein R; Chynn KY; Kourides IA
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid storm induced by TSH-secreting pituitary adenoma: a case report.
    Fujio S; Ashari ; Habu M; Yamahata H; Moinuddin FM; Bohara M; Arimura H; Nishijima Y; Arita K
    Endocr J; 2014; 61(11):1131-6. PubMed ID: 25132171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.